Home Blog Page 2491

Asia cohort of Phase 3 MARIPOSA study shows RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) achieved statistically significant and clinically meaningful improvement in overall survival versus osimertinib in EGFR-mutated non-small cell lung cancer

By
Advertorial Desk
-

Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more than one year

First and only chemotherapy-free combination in the first line setting to show survival improvement of this magnitude in a population with the highest-prevalence of EGFR-mutated lung cancer

SINGAPORE, Sept. 12, 2025 /PRNewswire/ — Johnson & Johnson today announced positive topline results for overall survival (OS) from the Asia cohort of the Phase 3 MARIPOSA study, evaluating amivantamab plus lazertinib as a first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or L858R substitution mutations. In this cohort, where EGFR mutations are more common than in other regions, the chemotherapy-free combination met the final pre-specified secondary endpoint of OS and showed a clinically meaningful and statistically significant survival benefit over osimertinib monotherapy. Median OS improvement is projected to exceed four years, surpassing osimertinib monotherapy by more than one year.

Asia has the largest population of patients with EGFR-mutated NSCLC worldwide, with an estimated prevalence of 30 to 40 percent compared to 10 to 15 percent in Europe and the United States.[1] Despite treatment advances, approximately 30 percent of patients do not reach second-line therapy, making the choice of first treatment critical.[2] Fewer than 20 percent of patients are alive five years after diagnosis.[3]

“EGFR-mutated NSCLC is more common in Asia Pacific than in other regions, which makes outcomes from the first treatment especially important,” said Byoung Chul Cho, M.D., Ph.D., Professor of Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine.* “Because of rapid disease progression and health system challenges, many patients will not have the chance to receive a second-line therapy. Therefore, the first treatment determines how the disease progresses over time. The MARIPOSA Asia cohort results show that survival can be significantly extended with amivantamab plus lazertinib in patients of Asian descent, helping them live longer.”

“For patients and families, every additional year means more time together and the chance to reach milestones that once felt out of reach,” said Kazuo Hasegawa, Founder of Lung Cancer Patients Network ONE STEP.** “The MARIPOSA Asia cohort results matter because they show that extending survival is possible in a disease where progress has often been measured in months.”

“Overall survival is the most meaningful measure of progress, and the MARIPOSA Asia cohort results reinforce the role of therapeutic innovations like amivantamab plus lazertinib in the first-line setting,” said Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific. “With its triple mode of action targeting EGFR and MET while also activating immune cells, amivantamab plus lazertinib addresses resistance that often limits tyrosine kinase inhibitor based therapy and delivers durable survival. These findings, with a median overall survival projected beyond four years, mark an important milestone for patients across Asia.”

MARIPOSA, which enrolled 1,074 patients, is a randomized, Phase 3 study evaluating amivantamab in combination with lazertinib versus osimertinib as a first-line treatment of patients with EGFR-mutated NSCLC. The primary endpoint was progression-free survival (PFS) (using RECIST v1.1 guidelines§) as assessed by blinded independent central review (BICR). Secondary endpoints included OS, objective response rate (ORR), duration of response (DOR), second progression-free survival (PFS2) and intracranial PFS.[4]

The safety profile of amivantamab plus lazertinib was consistent with the primary analysis and no new safety signals emerged with longer-term follow-up. Phase 2 amivantamab studies suggest that using prophylactic measures can help lower the risk of adverse events such as skin reactions, infusion-related reactions and venous thromboembolic events.[5],[6],[7]

Overall survival results from the Asia cohort will be presented at an upcoming congress. The combination of amivantamab and lazertinib is approved in the United States, Europe and the Asia-Pacific region in the Japan, China, Australia, Korea and Taiwan markets for first-line treatment for patients with EGFR-mutated NSCLC based on the global MARIPOSA Phase 3 study. 

About amivantamab  

Amivantamab-vmjw, a fully-human bispecific antibody targeting EGFR and MET with immune cell-directing activity, is approved in the U.S., Europe and five countries and markets in Asia-Pacific region in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations.

Amivantamab is approved in the U.S., Europe and nine countries and markets in Asia-Pacific region in combination with chemotherapy (carboplatin-pemetrexed) for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR TKI.

Amivantamab is approved in the U.S., Europe and eleven countries and markets in Asia-Pacific region in combination with chemotherapy (carboplatin and pemetrexed) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.  

Amivantamab is approved in the U.S., Europe and twelve countries and markets in Asia-Pacific region as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. 

About lazertinib

In 2018, Janssen Biotech, Inc., entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib (marketed as LECLAZA in South Korea). Lazertinib is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild-type EGFR. An analysis of the efficacy and safety of lazertinib from the Phase 3 LASER301 study was published in The Journal of Clinical Oncology in 2023.[8]

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[9],[10] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[11] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[12] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[12],[13],[14],[15],[16] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[17] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR TKIs is less than 20 percent.[18],[19] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[20] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[21] By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90 percent and 97 percent respectively.[22]

About Johnson & Johnson 

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at https://www.jnj.com or at http://www.innovativemedicine.jnj.com/. Follow us at @JNJInnovMed. Johnson & Johnson International (Singapore) Pte. Ltd is a Johnson & Johnson company.

Cautions Concerning Forward-Looking Statements 

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of amivantamab or lazertinib. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov, http://www.jnj.com, or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.       

*Professor Byoung Chul Cho has not been paid for any media work.

**Mr. Kazuo Hasegawa has served as a consultant to J&J; he has not been paid for any media work.

§ RECIST (version 1.1) refers to Response Evaluation Criteria in Solid Tumors, which is a standard way to measure how well solid tumors respond to treatment and is based on whether tumors shrink, stay the same or get bigger.

[1] Zhang YL, Yuan JQ, Wang KF, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993. doi:10.18632/oncotarget.12587

[2] Roeper J, et al. Risk of not receiving 2nd line therapy is high in EGFR mt+ pts: Real world data of certified lung cancer centers on treatment sequence in EGFR mt+ pts. J Clin Oncol. 2018;36(suppl):e21220. doi:10.1200/JCO.2018.36.15_suppl.e21220

[3] Sabari JK, Yu HA, Mahadevia PJ, et al. Overall survival in EGFR-mutant advanced non–small cell lung cancer treated with first-line osimertinib: a cohort study integrating clinical and biomarker data in the United States. J Thorac Oncol. Published online May 2, 2025. doi:10.1016/j.jtho.2025.04.010

[4] ClinicalTrials.gov. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA). https://classic.clinicaltrials.gov/ct2/show/NCT04487080. Accessed September 2025.

[5] Girard, et al. Preventing Moderate to Severe Dermatologic Adverse Events in First-line EGFR-mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib: Early Success of the COCOON Trial. 2025 European Lung Cancer Congress. March 27, 2025.

[6] Spira AI, et al. Preventing infusion-related reactions with intravenous amivantamab—results from SKIPPirr, a phase 2 study: a brief report. J Thorac Oncol. 2025;20(6):809-816.

[7] Leighl N, et al. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024;42(30):3593-3605.

[8] Cho BC, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: Results From LASER301. J Clin Oncol. 2023;41(26):4208-4217.

[9] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed September 2025.

[10] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed September 2025.

[11] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

[12] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. 2021 World Conference on Lung Cancer Annual Meeting; January 29, 2021.

[13] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.

[14] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. 2021 World Conference on Lung Cancer Annual Meeting; January 29, 2021.

[15] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

[16] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

[17] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed September 2025.

[18] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

[19] Lin JJ, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2016;11(4):556-65.

[20] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013; 12(2):220-9.

[21] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore. 

[22] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.

 

SUS ENVIRONMENT Takes Center Stage at WMAM 2025 with Cutting-Edge WtE and AI-Twin Digital in Malaysia

By
Advertorial Desk
-

SHANGHAI, Sept. 12, 2025 /PRNewswire/ — SUS ENVIRONMENT, a leading global environmental technology innovator, made a powerful impact at the Waste Management Association of Malaysia (WMAM) 20th Anniversary Annual Conference, held on at Royale Chulan Kuala Lumpur.

The event, themed “Smart Waste Management: Harnessing Technology for a Greener Tomorrow”, is one of the largest and most important platforms in Malaysia, bringing together government leaders, regulators, industry players, and waste management “warriors” from across the country and region. Distinguished guests attending the conference included:

  • YB Nga Kor Ming, Minister of Housing and Local Government (KPKT) 
  • Dato’ Azhar bin Yahya, Director General, Department of National Solid Waste Management (JPSPN)
  • YB Tuan Hee Loy Sian, Chairman of Solid Waste Management and Public Cleansing Corporation (SWCorp)
  • YB Khalid bin Mohamed, Chief Executive Officer of SWCorp

In addition, Mr. James Law, President of the International Solid Waste Association (ISWA), Mr. Xu Moqiang, Vice President of the China Association of Urban Environmental Sanitation (CAUES), and other representatives from international solid waste organizations attended the conference.

At the conference forum, Mr. Eric Zhan, CEO of SUS International, delivered a spotlight presentation. He outlined global development trends in waste-to-energy, emphasizing that China has made the greatest progress in the past decade, while Southeast Asia has now become the fastest-growing region. He also shared China’s best practices tailored to Malaysia’s waste profile, covering areas such as high-efficiency power generation, bottom ash utilization, zero-landfill fly ash treatment, AI and digital twin applications, and carbon emission monitoring.

At the SUS ENVIRONMENT exhibition booth, a 3D model of a waste-to-energy project and the company’s latest AI-Twin Digital technology were showcased. The WtE 3D model, combined with a complete incineration process display, allowed participants to gain a direct and intuitive understanding of the entire waste-to-energy process. Meanwhile, the AI-Twin Digital system recreated the real-time operational performance of the Xi’an SUS WtE project in the form of a full 3D digital model, brought vividly to life at the venue in Kuala Lumpur, Malaysia.

The Malaysian Minister of Housing, YB Nga Kor Ming, together with WMAM Chairman Mr. Ho De Leong, presented a gift to SUS ENVIRONMENT at the venue. On behalf of the company, Dr. Long Jisheng, Chairman of SUS ENVIRONMENT, reciprocated with “China’s Best Available Techniques (CBAT)“, for which he served as chief editor.

The Gala Dinner graced by the presence of mayors, city council representatives from across Malaysia, as well as senior leaders from JPSPN and SWCorp. During the evening, SUS’s leadership was further recognized with an Award of Excellence for Waste Management Initiatives, honouring the company’s outstanding contributions to advancing sustainable solutions in Malaysia. The award was presented by Mr. James Law, President of ISWA together with Mr. Ho De Leong, President of WMAM.

Through continuous innovation and localized practices, SUS is committed to working with partners across sectors to drive green transformation and sustainable development, contributing to a cleaner and smarter Malaysia.

 

Gemini Announces Pricing of Initial Public Offering

By
Advertorial Desk
-

NEW YORK, Sept. 12, 2025 /PRNewswire/ — Gemini Space Station, Inc. (“Gemini”), a global crypto platform, today announced the pricing of its initial public offering of 15,178,572 shares of Class A common stock at a public offering price of $28.00 per share. In connection with the offering, Gemini and the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 300,565 and 458,364 shares of Class A common stock, respectively, to cover over-allotments. Gemini will not receive any proceeds from any sale of shares by the selling stockholders. Gemini’s Class A common stock is expected to begin trading on the Nasdaq Global Select Market on September 12, 2025 under the ticker symbol “GEMI” and the offering is expected to close on September 15, 2025, subject to customary closing conditions.

Goldman Sachs & Co. LLC and Citigroup are acting as lead bookrunners. Morgan Stanley and Cantor are also acting as lead bookrunners. Evercore ISI, Mizuho, Truist Securities, Cohen & Company Capital Markets, Keefe, Bruyette & Woods, A Stifel Company, Needham & Company, and Rosenblatt are acting as bookrunners. Academy Securities, AmeriVet Securities, and Roberts & Ryan are acting as co-managers.

The offering is being made only by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by visiting EDGAR on the Securities and Exchange Commission’s (the “SEC”) website at www.sec.gov. Alternatively, copies of the prospectus may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, or email: prospectus-ny@ny.email.gs.com; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Tel: 800-831-9146).

A registration statement relating to these securities has been filed with, and declared effective by, the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Gemini

Gemini is a global crypto platform founded by Cameron and Tyler Winklevoss in 2014. Gemini offers a wide range of crypto products and services for individuals and institutions in over 60 countries. Gemini’s simple, reliable, and secure products are built to unlock the next era of financial, creative, and personal freedom.

Contacts

Investors
Gemini Investor Relations
Email: investors@gemini.com

Press
Natalie Rix
Email: press@gemini.com

Smartee and Shanghai Ninth People’s Hospital Win First Prize at Shanghai Science and Technology Progress Awards

By
Advertorial Desk
-

SHANGHAI, Sept. 12, 2025 /PRNewswire/ — Smartee Denti-Technology, a global innovator in invisible orthodontic solutions, together with Shanghai Ninth People’s Hospital affiliated with Shanghai Jiao Tong University School of Medicine, has been awarded the First Prize of the Shanghai Science and Technology Progress Award. This prestigious recognition highlights the two institutions’ joint achievements in advancing precision surgery for complex craniofacial deformities.

Award and Background:

The Shanghai Science and Technology Progress Award, established by the Shanghai Municipal People’s Government, is among the city’s most prestigious honors. It recognizes major scientific and technological achievements that drive original innovation in scientific discoveries and technological inventions, promote industrial transformation and strategic industry development, and advance urban safety, ecological health, and regional economic growth. Receiving the First Prize highlights the project’s significant contribution to both clinical medicine and digital healthcare innovation.

Project Overview:

The winning project, “Establishment and Application of a Key Technological System for Precision Surgery in Complex Craniofacial Deformities,” integrates the clinical expertise of Shanghai Ninth People’s Hospital’s Department of Oral and Craniomaxillofacial Surgery with Smartee’s leading capabilities in digital simulation and intelligent manufacturing. Together, the partners have developed a comprehensive technological system that improves diagnosis, planning, and treatment outcomes for patients with severe craniofacial anomalies.

Clinical Value:

Complex craniofacial deformities, often involving severe jaw developmental anomalies and malocclusion, require multi-disciplinary care and pose long-standing challenges for clinicians. This project establishes an integrated model that enhances surgical precision, reduces treatment risks, and enables personalized, patient-specific solutions.

Smartee’s Contribution and Impact:

As a pioneer in clear aligners and digital orthodontic technology, Smartee contributed its expertise by developing a comprehensive suite of tools for complex craniofacial cases. These include surgical planning systems, orthodontic-orthognathic case management software, integrated simulation and demonstration platforms, as well as intraoperative and postoperative clear guides. Together, these innovations form a full-process digital solution that supports joint orthodontic-orthognathic treatments, enhancing precision and efficiency in clinical practice.

Future Outlook:

Looking ahead, Smartee will continue to expand the application of these technologies to broader clinical settings, promoting international academic exchange and providing patients worldwide with access to safer and more effective orthodontic treatments.

To learn more about Smartee’s innovations in orthodontics, visit: www.smarteealigners.com

 

Major Content Update ‘Unconditional Love Phase 1’ Arrives in Persona5: The Phantom X

By
Advertorial Desk
-

TAIPEI, TAIWAN – Media OutReach Newswire – 12 September 2025 – Persona 5: The Phantom X has officially released Version 2.0, titled “Unconditional Love Phase 1.” This significant update introduces a wealth of new content, including a brand-new main story chapter, a new playable Phantom Thief, a new palace, a new area to explore, and a variety of in-game events and bundles.

Unconditional Love Phase 1

The Version 2.0 update introduces the newest 5 Star Phantom Thief, Ayaka Sakai, voiced by Yui Makino. Ayaka Sakai is a shy college student and musician who plays rhythm guitar. Despite her band’s breakup, her passion for music remains, leading her on a new journey.

PublisherTMPCwwuy7.jpg

Players can now dive into Chapter 3 of the main story, where they will team up with Riko to solve new problems and challenges. This chapter also unlocks a new palace, Dam, and the new explorable area of Kichijoji, where players can discover rewards and more.

To celebrate this major content release, the operations team has prepared a series of events and rewards for all players.

  • 7-Day Login Event: Log in for seven days during the event to earn a total of 20 Platinum Tickets and 20 Platinum Milicoins.
  • New Update Reward: Log in to claim 60 Thief’s Cognitite Shards, which can be redeemed for a specific Thief’s Cognitite.
  • Mission Completion Rewards: Complete objectives in the new Chapter 3 content to earn Meta Jewels, Joy Medals, and the exclusive event item, Mizuhiki Knots.

Additionally, fan-favourite Phantom Thieves, Ren Amamiya, is returning to idol contracts. During this limited-time event, players have an increased chance to obtain these highly sought-after characters. Don’t miss this opportunity to add them to your team!

Persona5: The Phantom X is now officially available for download on iOS, Android, and PC platforms in Southeast Asia.

– App Store: https://apps.apple.com/app/id6745494137
– Google Play Store: https://play.google.com/store/apps/details?id=sea.com.iwplay.p5x
– PC: https://p5x.pse.is/PCDL
Hashtag: #P5X #P5 #persona5x





The issuer is solely responsible for the content of this announcement.

Demand AI Group Secures $2.5 Million in Funding from International Institutional and Local Investors

By
Advertorial Desk
-

DENVER, Sept. 12, 2025 /PRNewswire/ — Demand AI Group Inc. (“Demand AI”), the fast-growing AI-driven B2B marketing and lead-generation company, today announced the successful close of a $2.5 million investment round backed by a syndicate of international institutional investors and strategic local partners.

Demand AI Group
Demand AI Group

The funding marks a significant milestone in Demand AI’s rapid global expansion. Since its inception earlier this year, the company has established operations across nine countries, delivering a next-generation AI-powered alternative to traditional lead-generation models. With its proprietary technology and proven leadership team—who previously scaled and exited Selling Simplified Group to IDG/Blackstone in 2022—Demand AI is uniquely positioned to transform the way businesses generate demand and connect with customers.

“We are thrilled to welcome both international institutions and local investors who share our vision of reshaping the B2B demand-generation industry with AI,” said Michael Whife, CEO of Demand AI Group. “This funding provides us with the runway to accelerate growth, expand into new markets, and seize on acquisition opportunities as the industry continues to shift away from legacy models.”

The $2.5M raise will be used to:
-Accelerate global expansion with new offices across Europe and Asia-Pacific.
-Scale the sales and delivery teams to meet surging demand from enterprise clients.
-Invest in proprietary AI-driven systems to further differentiate Demand AI’s platform and services.
-Explore strategic acquisitions to consolidate market share in a rapidly evolving industry.

Demand AI is poised for unprecedented growth as businesses embrace conversational AI and intelligent automation, signaling a major shift in how the industry approaches demand generation.

Demand AI continues to attract top talent globally, with recent leadership hires in Europe, the Middle East, and Asia-Pacific, further strengthening its ability to deliver at scale.

About Demand AI Group Inc.
Demand AI Group is a global AI-driven demand-generation company headquartered in Denver, Colorado. Founded by Michael and Charlie Whife, industry veterans with a proven track record of scaling and exiting global businesses, Demand AI provides enterprises with AI-powered marketing, lead generation, and content solutions. The company currently operates in nine countries across Europe, Asia, and North America, delivering measurable results and industry-leading ROI.

 

“My Yunnan Flavor” Topic Challenge to Be Launched

By
Advertorial Desk
-

KUNMING, China, Sept. 12, 2025 /PRNewswire/ — The “My Yunnan Flavor” topic challenge will be launched by Yunnan SYNDA Information Industry Co., Ltd. From August 20, 2025 to September 30, 2025, creators around the world are invited to capture Yunnan’s distinctive tastes and bustling market life in short, shareable videos. Anchored by the five-flavor theme — Sour, Sweet, Bitter, Spicy, Umami — the campaign highlights local dishes, spring market rituals and everyday street culture, while celebrating five corresponding cultural ethos that make Yunnan uniquely vibrant.

Beyond the official themed video series, the event features a playful “100 Yuan Market Challenge,” where creators explore local markets with just 100 RMB to discover iconic snacks. A series of short interviews with foreign visitors will offer fresh, cross-cultural perspectives, and select collaborations with international KOLs will help bring Yunnan’s flavors to a global audience. Top submissions will be promoted across our channels and tied into offline market events to maximize engagement and impact.

How to join: Post your original video with the hashtag #MyYunnanFlavor, tag @visityunnan, or email entries to lilyzhangll727@gmail.com; Follow our official account for full rules and the latest updates — we can’t wait to see Yunnan through your lens!

Official Links：

YouTube: https://www.youtube.com/@visityunnan21

TikTok: https://www.tiktok.com/@visityunnan

The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration

By
Advertorial Desk
-

SUZHOU, China, Sept. 12, 2025 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK) announced that the New Drug Application (NDA) for anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), has been accepted by the National Medical Products Administration (NMPA). KN026 has been applied for as a Class 1 therapeutic biological product and the indication is for use in combination with chemotherapy for the treatment of patients with HER2-positive locally advanced, recurrent, or metastatic gastric or gastroesophageal junction cancer who have failed at least one prior systemic therapy (which must include trastuzumab in combination with chemotherapy).

This NDA for KN026 is primarily based on a pivotal Phase II/III clinical trial (Study ID: KN026-001). Results from the first interim analysis of the Phase III clinical study demonstrated that, compared to the current standard of care, KN026 combined with chemotherapy significantly improved clinical efficacy, by prolonging progression-free survival (PFS) and overall survival (OS). Furthermore, the combination showed no new safety signals, with a low incidence of cardiotoxicity and low immunogenicity in terms of safety profile. Previously, results from the Phase II clinical study, presented at the 2024 European Society for Medical Oncology (ESMO) Congress, showed that KN026 in combination with chemotherapy achieved an objective response rate (ORR) of 40.0%, with a median PFS of 8.6 months as assessed by the independent review committee (IRC). KN026 was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the NMPA on November 4, 2023, and received Priority Review status on August 28, 2025.

Currently, there are no approved anti-HER2 therapies for the second-line treatment of HER2-positive gastric cancer. KN026 is the first HER2 bispecific antibody to demonstrate positive results in the second-line treatment of gastric cancer in China. Meanwhile, multiple pivotal Phase III clinical studies of KN026 in gastric cancer and breast cancer are undergoing smoothly, with the aim of benefiting more patients.

About KN026

KN026 is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). KN026 can simultaneously bind two non-overlapping epitopes of HER2, leading to HER2 signal blockade. KN026 has demonstrated better tumor inhibition in HER2-positive tumor cell lines compared with trastuzumab and pertuzumab in combination. Additionally, KN026 has also shown inhibitory effect on tumor cells with trastuzumab-resistant cell lines.

The results of multiple clinical studies in different stages showed that KN026 has significant anti-tumor activities, even in heavily pretreated patients with HER2-positive breast cancer (BC) and gastric cancer (GC), including those with prior anti-HER2 treatment. Currently, several pivotal clinical trials of KN026 for the second-line or above treatment of HER2-positive GC/gastroesophageal junction cancer (GEJ), the first-line treatment of HER2-positive BC, neoadjuvant treatment for HER2-positive BC are being conducted. KN026 in combination with chemotherapy for the treatment of patients with HER2-positive GC (including GEJ) who have failed first-line standard treatment was granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA).

In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China, pursuant to which, JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan).

About Alphamab Oncology

Alphamab Oncology is an innovative biopharmaceutical company focusing on oncology therapeutics. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966.

By leveraging its proprietary core technology platforms including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payload, dual-payload antibody conjugation, and subcutaneous high concentration formulation for biologics, the Company has established a product portfolio with differentiated innovation and global competitiveness, covering cutting-edge areas such as antibody-drug conjugates (ADCs), bispecific antibodies, and single-domain antibodies.

The Company has one product approved for marketing (Envafolimab, the world’s first subcutaneously injectable PD-(L)1 inhibitor), which has made a significant breakthrough in the convenience and accessibility of cancer treatment. Additionally, the Company has multiple bispecific antibodies and bispecific ADCs in clinical stage, while rapidly advancing the preclinical pipeline prioritizing bispecific ADCs and dual-payload ADCs. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, ArriVent, and Glenmark.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.

 

1...2,4902,4912,492...6,512Page 2,491 of 6,512